26P Capmatinib combined with EGFR-TKI in EGFR-mutant non-small cell lung cancer with MET overexpression and acquired resistance to prior EGFR inhibitors

adverse events (AEs) of any grade were anemia (18.3%), urinary tract infection (11.7%), and decreased neutrophil count (10.0%).No new safety signals were identified compared with the established profiles of each individual drug. Conclusions:The all-oral combination of aumolertinib and etoposide demonstrated promising antitumor activity and a manageable safety profile in treatment-naive EGFR-mutated NSCLC.This regimen offers a potential convenient, outpatient-based therapeutic strategy worthy of further validation.Clinical trial identification: NCT06463171.